Cambridge NeuroScience Inc. on Thursday said it has beenawarded a $50,000 Phase I small business innovation researchgrant from the National Institutes of Health to identifyglutamate antagonist compounds that could preventneurological damage during coronary artery bypass surgery.
The Cambridge, Mass., company (NASDAQ:CNSI) estimated thatup to 50 percent of the 400,000 patients who undergo majorcardiac surgery in the United States each year experienceneurological complications.
The company has received more than $1 million in SBIR grantsin the past 12 months.
(c) 1997 American Health Consultants. All rights reserved.